ClinicalTrials.gg
CompletedNCT03962049Updated Jan 13, 2020

Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function

A Phase 1 interventional study of Linzagolix in Hepatic Impairment and Healthy Participants, sponsored by ObsEva SA. Completed at 2 sites in United States. Open to female participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-13.

Sponsored by ObsEva SA · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Oct 2019, 7 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies in Hepatic Insufficiency with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Hepatic Insufficiency · United States.

Enrollment
30th of 48
24 · median 28
Started
2019
with 4 others
Phase 1
42 of 52
3 open now
Registered
33rd of 52
by date

Among the 52 studies in Hepatic Insufficiency with a site in United States, this one is the 30th largest by enrollment of the 48 interventional ones that give a count, is one of 5 that started in 2019, is one of 42 in phase 1, and was the 33rd registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

3 of the 52 studies in Hepatic Insufficiency with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Hepatic Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the pharmacokinetics (PK) of linzagolix in subjects with varying degrees of impaired hepatic function compared to match control subjects with normal hepatic function

Read the detailed description

This is a Phase 1, non-randomized, open label, single-dose study to evaluate the effect of varying degrees of impaired hepatic function (i.e., mild, moderate, and severe Hepatic Impairment (HI)) on the PK, safety, and tolerability of linzagolix and its major metabolite, KP017.

Up to 28 adult female participants will be enrolled.

03

Conditions studied

  • Hepatic Impairment
  • Healthy Participants

Keywords

  • Linzagolix
  • OBE2109
  • Hepatic Impairment
  • Hepatic Insufficiency
  • Liver Diseases
  • Clinical pharmacology study
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Hepatic Impaired Subjects

  1. Adult female, 18-75 years of age, inclusive, at screening
  2. Has a ≥ 18.0 and ≤ 42.0 kg/m\^2 and weight ≥ 40 kg, at screening
  3. Aside from HI, be sufficiently healthy for study participation based upon medical history, physical examination, vital signs, (ECGs), and screening clinical laboratory profiles, as deemed by the Principal Investigator (PI) or designee
  4. Has a score on the scale at screening as follows:

    • Severe HI: ≥ 10 and ≤ 15
    • Moderate HI: ≥ 7 and ≤ 9
    • Mild HI: ≥ 5 and ≤ 6
  5. Has a diagnosis of chronic (> 6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic insufficiency with features of cirrhosis due to any etiology

Healthy Subjects

  1. Healthy adult female will be matched based upon age and BMI
  2. Medically healthy with no medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee.

Key Exclusion Criteria:

Hepatic Impaired Subjects

  1. Has a clinically active Grade 3 or 4 encephalopathy
  2. Has fluctuating or rapidly deteriorating hepatic function within the screening period, and up to 30 days prior to Day 1, in the opinion of the PI and Sponsor
  3. Has history of liver or other solid organ transplant
  4. Had any major surgery within 4 weeks prior to dosing
  5. Has a surgical (e.g., hepatectomy, nephrectomy, digestive organ resection) or medical condition other than HI which might significantly alter the absorption, distribution, metabolism, or excretion of linzagolix and its metabolites, or which may jeopardize the subject's safety in case of participation in the study in the opinion of the PI or designee

Healthy Subjects

  1. Has any clinically significant illness, as judged by the PI or designee, within 4 weeks prior to dosing
  2. Has laboratory values at screening or check-in which are deemed to be clinically significant (especially derangement within liver function test), unless agreed in advance by the PI and the Sponsor
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Normal Hepatic Function

    Healthy participants with Normal Hepatic Function

    Drug: Linzagolix

  • Experimental
    Mild Hepatic Impairment

    Presence of Mild Hepatic Impairment (score of 5 to 6, on the Child Pugh scale and with features of cirrhosis due to any etiology)

    Drug: Linzagolix

  • Experimental
    Moderate Hepatic Impairment

    Presence of Moderate Hepatic Impairment (score of 7 to 9, on the Child Pugh scale and with features of cirrhosis due to any etiology)

    Drug: Linzagolix

  • Experimental
    Severe Hepatic Impairment

    Presence of Severe Hepatic Impairment (score of 10 to 15 on the Child Pugh scale and with features of cirrhosis due to any etiology)

    Drug: Linzagolix

Interventions

  • A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions

06

What researchers measure

Primary outcomes

  1. Plasma pharmacokinetic (PK) parameter Cmax of linzagolix and of KP017

    Measurement of effect of hepatic impairment on PK of linzagolix and its metabolite KP017 by assessment of the maximum plasma concentration (Cmax). Cmax directly determined from the plasma concentration-time profiles

    Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose

  2. Plasma PK parameter Tmax of linzagolix and of KP017

    Measurement of effect of hepatic impairment on PK of linzagolix and its metabolite KP017 by assessment of the Time to reach Cmax (Tmax)

    Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose

  3. Plasma PK parameter AUC0-t of linzagolix and of KP017

    Measurement of effect of hepatic impairment on PK of linzagolix and its metabolite KP017 by assessment of the AUC0-t (area under the concentration time curve, from time 0 to the last observed non-zero concentration)

    Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose

  4. Plasma PK parameter T1/2 of linzagolix and of KP017

    Measurement of effect of hepatic impairment on PK of linzagolix and its metabolite KP017 by assessment of the T1/2 (Terminal half life)

    Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose

Secondary outcomes

  1. Treatment emergent Adverse Events

    Assessment of safety and tolerability of a single dose of linzagolix in hepatic impaired subjects compared with healthy control subjects by assessing the number, frequency and severity of treatment emergent Adverse Events

    Time frame: Day 1 to 14 days post-dose

07

Study locations

2 sites
  • Clinical Site
    Hialeah, Florida 33014, United States
  • Clinical Site
    Orlando, Florida 32809, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Oct 2019, 5 months.

Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 5 months is below that.

Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2019
First posted
May 23, 2019
StartActual
May 15, 2019
Primary completionActual
Oct 23, 2019
CompletionActual
Nov 1, 2019
Last update
Jan 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03962049
Lead sponsor
ObsEva SA
Responsible party
Sponsor
First posted
May 23, 2019
Start date
May 15, 2019
Primary completion
Oct 23, 2019
Completion
Nov 1, 2019
Last update
Jan 13, 2020

Study contacts

ObsEva SA
study director · Geneva

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linzagolix

Start the discussion